The use of anti-osteoporosis drugs after fractures is controversial due to their impact on bone remodeling, which is essential for fracture healing.7 Teriparatide, recombinant human parathyroid hormone (rhPTH1-34), is the most commonly used anabolic agent in the clinic. Here, PTH is linked to osteoporosis.